MW 250.17 Da, Purity >97%. Selective iNOS inhibitor, 5000-fold selective over eNOS (Kd values are ≤7 nM, 2 μM and 50 μM at human iNOS, nNOS and eNOS, respectively).
ACEE, ACES_HUMAN, ACLS, AI838772, AIS, ANDR_HUMAN, AR, AR8, ARACHE, AW493413, Acetylcholinesterase, Androgen nuclear receptor variant 2, Androgen receptor, Androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease), Antigen NY-CO-13, Apoptosis related acetylcholinesterase, Atherosclerosis, susceptibility to, included, BCC7, BNOS, CAR, CAR BETA, CARA, Car 1, Cellular tumor antigen p53, Constitutive NOS, Constitutive activator of retinoid response, Constitutive active response, Constitutive androstane receptor, DHTR, DKFZp686N23123, DNA binding protein, Dihydro testosterone receptor, Dihydrotestosterone receptor (DHTR), ER, ER-alpha, ER-beta, ERR a, ERR-alpha, ERR1 protein, ERR1_HUMAN, ER[a], ER[b], ESR, ESR B, ESR BETA, ESR1_HUMAN, ESRA, ESRL 1, ESRR A, ESTR B, Era, Erb, Erb2, Estr, Estra, Estradiol Receptor alpha, Estradiol Receptor beta, Estradiol receptor, Estrogen Receptor 1, Estrogen Receptor 2, Estrogen receptor, Estrogen receptor 1 (alpha), Estrogen receptor 2 (ER beta), Estrogen receptor 2 ER beta, Estrogen receptor alpha, Estrogen receptor beta 4, Estrogen receptor related 1, Estrogen receptor-like 1, Estrogen resistance, included, Estrogen-related receptor alpha, Estrra, FLJ11090, FLJ92943, GCPS, GLI Kruppel family member GLI 3, GLI Kruppel family member GLI3 (Greig cephalopolysyndactyly syndrome), GLI family zinc finger 3, GLI3 C-terminally truncated form, GLI3 form of 190 kDa, GLI3 form of 83 kDa, GLI3 full length protein, GLI3-190, GLI3-83, GLI3FL, GLI3_HUMAN, Glioma associated oncogene family zinc finger 3, HDL cholesterol, augmented response of, to hormone replacement, included, HEP-NOS, HUMARA, HYSP1, Hepatocyte NOS, IHPS 1, Inducible NO synthase, Inducible NOS, Inducible nitric oxide synthase, KD, Kennedy disease (KD), LFS1, MAC NOS, MB67, MGC104252, MGC112732, MGC97144, Macrophage NOS, Mutant tumor protein 53, Myocardial infarction, susceptibility to, included, N-ACHE, N-NOS, NC-NOS, NOS, NOS type I, NOS type II, NOS2A, NOS2A, Inducible, Hepatocyte, NOS2_HUMAN, NR1I3_HUMAN, NR3A1, NR3A2, NR3B1, NR3C4, Neuronal NOS, Nitric oxide synthase, Nitric oxide synthase 1, Nitric oxide synthase 1 neuronal, Nitric oxide synthase 2 inducible, Nitric oxide synthase 2 inducible macrophage, Nitric oxide synthase brain, Nitric oxide synthase inducible, Nos II, Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 3 group A member 1, Nuclear receptor subfamily 3 group A member 2, Nuclear receptor subfamily 3 group B member 1, Nuclear receptor subfamily 3 group C member 4, Nuclear receptor subfamily 3 group C member 4 (NR3C4), OTTHUMP00000017718, OTTHUMP00000017719, Oncogene GLI3, Orphan nuclear receptor MB67, Orphan nuclear receptor NR1I3, P53_HUMAN, PAP A, PAPB, PPD IV, Peptidyl-cysteine S-nitrosylase NOS2, Phosphoprotein p53, RNESTROR, RP24-311F12.2, SBMA, SCAN1, SMAX1, Spinal and bulbar muscular atrophy, Spinal and bulbar muscular atrophy (SBMA), Steroid hormone receptor ERR1, TFM, TRP53, TYDP, TYDP1_HUMAN, Testicular Feminization (TFM), Tp53, Transcriptional activator GLI3, Transcriptional repressor GLI3R, Transformation related protein 53, Tumor protein 53, Tumor protein p53, Tumor suppressor p53, Tyr-DNA phosphodiesterase 1, Tyrosyl-DNA phosphodiesterase 1, YT, YT blood group, Zinc finger protein GLI 3, androgen receptor splice variant 4b, constitutive active receptor, constitutive androstane nuclear receptor variant 2, constitutive androstane nuclear receptor variant 3, constitutive androstane nuclear receptor variant 4, constitutive androstane nuclear receptor variant 5, estrogen receptor related receptor alpha, hERR1, iNOS, inducible, neuronal Nitric Oxide Synthase, nitric oxide synthase 2A (inducible, hepatocytes), nitric oxide synthase, macrophage, orphan nuclear hormone receptor, p53 tumor suppressor, tumor antigen p55
MW 250.17 Da, Purity >97%. Selective iNOS inhibitor, 5000-fold selective over eNOS (Kd values are ≤7 nM, 2 μM and 50 μM at human iNOS, nNOS and eNOS, respectively).
Soluble in water to 100 mM.
Selective iNOS inhibitor, 5000-fold selective over eNOS (Kd values are ≤7 nM, 2 μM and 50 μM at human iNOS, nNOS and eNOS, respectively).
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2D chemical structure image of ab120165, 1400W, iNOS inhibitor
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com